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Abstract: ATP-binding cassette (ABC) transporters, such as breast cancer resistance protein (BCRP),
are key players in resistance to multiple anti-cancer drugs, leading to cancer treatment failure and
cancer-related death. Currently, there are no clinically approved drugs for reversal of cancer drug
resistance caused by ABC transporters. This study investigated if a novel drug candidate, SCO-201,
could inhibit BCRP and reverse BCRP-mediated drug resistance. We applied in vitro cell viability
assays in SN-38 (7-Ethyl-10-hydroxycamptothecin)-resistant colon cancer cells and in non-cancer
cells with ectopic expression of BCRP. SCO-201 reversed resistance to SN-38 (active metabolite of
irinotecan) in both model systems. Dye efflux assays, bidirectional transport assays, and ATPase
assays demonstrated that SCO-201 inhibits BCRP. In silico interaction analyses supported the ATPase
assay data and suggest that SCO-201 competes with SN-38 for the BCRP drug-binding site. To analyze
for inhibition of other transporters or cytochrome P450 (CYP) enzymes, we performed enzyme and
transporter assays by in vitro drug metabolism and pharmacokinetics studies, which demonstrated
that SCO-201 selectively inhibited BCRP and neither inhibited nor induced CYPs. We conclude
that SCO-201 is a specific, potent, and potentially non-toxic drug candidate for the reversal of
BCRP-mediated resistance in cancer cells.
Keywords: multidrug resistance in cancer; drug efflux pumps; ATP-binding cassette transporter;
breast cancer resistance protein (BCRP); ABCG2; pyrazolo-pyrimidine derivative; SCO-201
1. Introduction
Chemotherapy resistance is considered the single most important obstacle to greater success
with chemotherapy for cancer patients [1–3]. Although many cancer patients initially benefit from
chemotherapy treatment, a large proportion of treatments fail due to acquisition of resistance to
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multiple anti-cancer drugs. This phenomenon is known as multidrug resistance (MDR) and refers
to the concurrent development of cross-resistance to many chemically diverse anti-cancer agents [4].
MDR results in poor prognosis and decreased survival rate of cancer patients, and strategies to
circumvent MDR are therefore highly needed [3,5]. The mechanisms underlying MDR are complex and
include many different tumor survival mechanisms [6]. Overexpression of drug expelling ATP-binding
cassette (ABC) transporters seems to be an important mechanism of MDR in cancer cells [7]. Today,
the most extensively studied and characterized ABC transporters, found to be involved in cancer
MDR, are (a) multidrug resistance protein 1/P-glycoprotein (MDR1/P-gp), encoded by the ABCB1 gene;
(b) multidrug resistance-associated protein 1 (MRP1), encoded by the ABCC1 gene; and (c) breast cancer
resistance protein (BCRP), encoded by the ABCG2 gene [8]. ABC transporters are normally expressed in
tissues such as the intestines, brain, liver, and placenta, where they prevent xenobiotic substrates from
accumulating [7]. The ABC transporters are transmembrane proteins that utilize ATP hydrolysis to drive
the active transport of substrates from the cytoplasmic site to the extracellular space [9]. The transporters
consist of two transmembrane domains (TMDs), able to undergo a conformational change that triggers
the removal of the substrate, and two cytoplasmic nucleotide-binding domains (NBDs) that bind
and hydrolyze ATP [10]. Due to a broad drug specificity, ABC transporters can efflux many different
anticancer agents, thus resulting in MDR [7,9]. BCRP (ABCG2) is a 72 kDa half-transporter that acts
as a homomeric dimer, and so far, BCRP is known to mediate resistance to a variety of anti-cancer
agents, among these the chemotherapeutic agents SN-38, topotecan, mitoxantrone, doxorubicin, and
daunorubicin [11–16]. SN-38 (Figure 1) is the active metabolite of irinotecan (Camptosar) and is
especially important in the treatment of gastrointestinal cancers such as colorectal cancer [17] and
pancreatic cancer (European Society for Medical Oncology (ESMO) guidelines for pancreatic cancer).
Several studies have indicated that high cancer cell levels of BCRP is the key player in SN-38 resistance,
and BCRP thus hinders successful treatment of metastatic gastrointestinal cancer patients [11–16].
Mitoxantrone was the first chemotherapy to be identified as a substrate of BCRP, and BCRP was found
to be involved in mitoxantrone-resistant breast cancer, thus giving BCRP its name [13].
During the last 40 years, researchers have tried to develop non-toxic, highly potent, and efficacious
drugs that are able to reverse ABC-transporter-mediated MDR [7,9,17–19]. These MDR-reversing
agents, also known as re-sensitizing agents or chemo-sensitizers, act by either inhibiting the expression
of ABC transporters or by directly inhibiting the transport function, and thereby restore the sensitivity
of the cancer cells to anti-cancer agents [9,10]. The compound fumitremorgin C was the first BCRP
inhibitor to be identified, and although it was found to have a high inhibitory potency, neurotoxic side
effects prevented the clinical use of this compound [20,21]. To prevent these side effects, researchers
synthesized new different fumitremorgin C analogues, for instance, the potent BCRP inhibitor
Ko143 [22,23]. Nonetheless, these analogues, including Ko143, were not stable in plasma, still caused
the side effects, and could not be used in the clinic [23]. Other known ABC transporter inhibitors
include verapamil, tariquidar, and valspodar (PSC833), which all inhibit MDR1/P-gp [9]. However,
despite a long list of different potent inhibitors, none of these have been approved for clinical use.
The lack of ABC transporter inhibitors in clinical use can be attributed to several issues: (1) the
inhibitors specifically only inhibit one transporter, (2) the inhibitors exhibit a significant degree of
toxicity, (3) clinical studies were poorly designed—inhibitors were not combined with the drug that
the patients had proved to be resistant to—and the studies lacked randomization, and (4) lack of
companion diagnostic tests to optimize patients’ selection and treatment [1,7,9]. Thus, new strategies
are greatly needed to improve the treatment success and survival rate of cancer patients with MDR.
To identify potential new compounds that interfere with common drug resistance mechanisms,
such as the overexpression of BCRP, we previously established the DEN-50R screening platform.
This platform consists of isogenic pairs of drug-sensitive and drug-resistant patient-derived cancer
cell lines, for instance, colorectal, breast, prostate, and pancreatic cancer [24]. These resistant cell lines
were established by exposing chemotherapy-sensitive cells to gradually increasing concentrations of
chemotherapy over a period of 8–10 months [25]. We thoroughly characterized these drug-resistant
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cell lines to identify important drug resistance mechanisms [25–30]. In accordance with several other
studies with in vitro model systems [31], we found that BCRP overexpression was a key player of
resistance to SN-38 [25]. Using our DEN-50R screening platform, we found that pyrazolo-pyrimidine
derivatives might serve as potential inhibitors of drug resistance in these cell lines. One of the hits
from the drug screening was the pyrazolo-pyrimidine derivative SCO-201 (previously OBR-5-340)
(Figure 1). These preliminary data indicated that SCO-201, which is previously known as a potent viral
capsid inhibitor, might serve as a potential inhibitor of drug resistance [32,33]. Interestingly, in a study
by Burkhart et al. (2009) [34], it was demonstrated that pyrazolo-pyrimidine derivatives comprise a
prominent structural class of selective and potent ABC transporter inhibitors, with low toxicity and
low risk of increased chemotherapy-mediated toxicity [19,34].
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metabolite of irinotecan, SN-38. Graphics produced using Maestro, Schrödinger 2019-3, limited liability
company (LLC), New York, NY, 2019. SN-38 structure obtained from PubChem Database [35,36].
On the basis of these findings, the aim of this study was to clarify if SCO-201 re-sensitizes cancer
cells to chemotherapy substrates of BCRP. An additional aim was to investigate any potential risks
of pharmacokinetic interactions of SCO-201, which was investigated by testing the effect of SCO-201
on cytochrome P450 enzymes and efflux/uptake transporters. Our study is the first to show that
SCO-201 competitively inhibits the transport activity of BCRP, triggers the accumulation of BCRP
dye substrate, and re-sensitizes cancer cells to chemotherapy in two different in vitro models of
BCRP-mediated resistance. Moreover, in vitro drug metabolism and pharmacokinetics (DMPK) data
suggest that SCO-201 will not influence metabolism of other drugs by the cytochrome P450 (CYP)
system. This indicates that SCO-201 is not likely to increase the risk of pharmacokinetic interactions
with chemotherapy that are metabolized by the CYP system. The present data warrant further studies
including regulatory toxicity and ADME (absorption, distribution, metabolism, and excretion) studies
according to good laboratory practice (GLP) in order to initiate clinical development [35,36].
2. Materials and Methods
2.1. Reagents and Antibodies
DMSO, SN-38, Ko143, topotecan, mitoxantrone, Hoechst 33342, MTT reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), primary antibody for β-actin (mAb A5441),
PREDEASY SB-MDR1/P-gp Hi5, and SB-BCRP-M ATPase assays kits (Solvo Biotechnology) were
all purchased from Sigma-Aldrich/Merck (Schnelldorf, Germany). PSC833 was purchased from
Tocris/Bio-techne (Abingdon, UK). The primary antibody for BCRP (mAb BXP-21) was purchased from
Abcam (Cambridge, UK).
Plasticware, such as T-75 culture flasks and Transwell permeable supports (1.12 cm2, 0.4 µm
pores), were purchased from Corning, Fisher Scientific (Slangerup, Denmark). Cell culture reagents
such as Hank’s balanced salt solution (HBSS) was purchased from Life Technologies (Taastrup,
Denmark); fetal bovine serum (FBS) from Gibco, Fischer Scientific (Slangerup, Denmark); penicillin
and streptomycin were acquired from Bio Whittaker Cambrex (Vallensbaek, Denmark); Dulbecco’s
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modified Eagle’s medium, bovine serum albumin (BSA), and Minimum Essential Media (MEM)
nonessential amino acids were purchased from Sigma-Aldrich (Brøndby, Denmark); whereas
2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) was purchased from AppliChem
GmbH (Darmstadt, Germany). [3H]-Estrone-3-sulfate (51.8 Ci/mmol), [14C]-mannitol (0.06 Ci/mmol),
and Ultima Gold scintillation fluid was purchased from PerkinElmer (Boston, MA, USA).
All drugs were dissolved in DMSO, except mitoxantrone, which was dissolved in ethanol.
2.2. Cell Lines and Culture Conditions
All cell lines were maintained at 37 ◦C in a humidified 5% CO2 atmosphere. The Madin-Darby
Canine Kidney (MDCK)-II-BCRP cell line was a kind gift from Dr. A. Schinkel (The Netherlands Cancer
Institute, Amsterdam, The Netherlands [29,30]) and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS), 50 µg/mL streptomycin, 50 U/mL penicillin G,
and 2 mM l-glutamine. The parental drug-sensitive (HT29PAR), obtained from the National Cancer
Institute (NCI)/Development Therapeutics Program, and SN-38-resistant (HT29SN-38-RES) cell lines were
cultured in Gibco Roswell Park Memorial Institute (RPMI) 1640–GlutaMAX medium supplemented
with 10% FCS [25].
2.3. Western Blot Analysis
The proteins of HT29 cell lysates were separated with SDS-PAGE and transferred to nitrocellulose
membranes. After blocking the membrane with 5% skimmed milk in 1× Tris-Buffered Saline,
0.1% Tween® 20 Detergent (TBS-T), the membrane were incubated with primary monoclonal
antibodies: anti-BCRP (BXP-21; 1:1000) and β-actin (1:500,000) overnight at 4 ◦C, and thereafter
with HRP-conjugated secondary antibody (1:4000) for 1 h. Bands were detected using Enhanced
Chemiluminescence (ECL) peroxide solution and luminol/enhancer solution (Clarity Western ECL
Substrate, Bio-Rad Laboratories (Copenhagen, Denmark)) for 5 min. Images were obtained with the
UVP Biospectrum imaging system (VisionWorks software, version LS 7.0.1).
2.4. MDR Reversal Analysis with MTT Assay
Cells were seeded in Nunc 96-well plates (2000 or 8000 cells/well for the MDCK-II and HT29 cells,
respectively). Following cell attachment (12–24 h), drugs were added to a total volume of 200 µL.
Control conditions consisted of full growth medium. All treatments were performed in triplicate.
Following 72 h of drug exposure, MTT reagent was added for either 1 h (MDCK-II) or 3 h (HT29).
For cell lysis and solubilization of the formazan crystals, DMSO was added to the MDCK-II cells,
whereas acidified (0.02 M HCl) sodium dodecyl sulphate was added to the HT29 cells. Optical densities
were measured with a microplate spectrophotometer at either 544 nm and 710 nm (background) for
the MDCK-II cells or 570 nm and 670 nm (background) for the HT29 cells. Background optical density
values were subtracted, and the average optical densities were calculated. Cell viability was calculated
as percentage of untreated control cells. The mean IC50 values were determined using GraphPad
Prism (version 6.0, San Diego, CA, USA). The drug sensitivity analysis was carried out at least three
independent times and representative data is shown.
2.5. Bidirectional Transport Assay
Bidirectional transport experiments with [3H]-estrone-3-sulfate were completed with monolayers
of Caco-2 cells from the American Type Culture Collection (ATCC) cultured on Transwell permeable
supports for 27 days in Dulbecco’s modified Eagle’s medium, supplemented with 10% FBS, 10 µL·mL−1
nonessential amino acids (×100), and 100 U·mL−1 to 100 µg·mL−1 penicillin-streptomycin solution.
The transepithelial electrical resistance was measured across Caco-2 cell monolayers with an Endohm
12-cup electrode chamber (World Precision Instruments Inc., Sarasota, FL, USA) connected volt meter
(EVOM, World Precision Instruments Inc., Sarasota, FL, USA) to ensure that cell monolayers were
electrically tight before initiating transport experiments. Cell monolayers were allowed to equilibrate
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to room temperature before the resistance was measured. Prior to initiating the transport experiments,
the cell monolayers were pre-incubated in transport buffer (HBSS supplemented with 10 mM HEPES,
pH 7.4, and 0.05 % BSA) for 30 min. Transport experiments were started by replacing the blank transport
buffer in the donor compartment with transport buffer containing [3H]-estrone-3-sulfate (1 µCi/mL)
and [14C]-mannitol (0.8 µCi/mL) with or without 10 µM SCO-201. For transport experiments in the
apical to basolateral direction, samples of 100 µL were taken from the basoteral compartment (volume
1 mL) at t = 15, 30, 45, 60, 90, and 120 min. From transport experiments in the basolateral to apical
direction, samples of 50 µL were taken from the apical compartment (volume 0.5 mL) at the same
time points. The withdrawn sample volume from the acceptor compartments were immediately
replaced with an equal volume of blank transport buffer. The withdrawn samples were pipetted
into scintillation vials and mixed with 2 mL of scintillation fluid. The radioactivity of the samples
was determined by means of liquid scintillation (Packard Tri-Carb 2910 TR, PerkinElmer, Waltham,
MA, USA). Transport of mannitol was measured to validate the barrier integrity of the Caco-2 cell
monolayers. The overall average apparent permeability of mannitol across Caco-2 cell monolayers was
2.1 ± 0.4 × 10−7 cm·s−1 (n = 3, total N = 9), which is within the expected range for mannitol permeability
across intact monolayers of Caco-2 cells.
Data treatment: The accumulated amount of compound (Qt, nmol) appearing in the donor
compartment was plotted against time. The steady-state flux of compound was calculated as the
slope of the linear part of this plot, thus correcting for lag-time effects. The apparent permeability was







where J represents the steady state flux (nmol·cm−2·min−1), C0 represents the initial concentration
in the donor compartment, At denotes the area of the permeable support (1.12 cm2), and Qt is the
accumulated amount of compound (nmol) in the receiver compartment at time t (min).
The ratio between apparent permeability in the basolateral to apical direction and the apparent
permeability in the opposite direction (efflux ratio = PB−APA−B ) was used as a measure of active
efflux transport.
2.6. Cellular Dye Efflux Assay
2.6.1. HT29 Cells
HT29 cells were seeded either into a 96-well Nunclon plate (Thermo Fisher Scientific, Roskilde,
Denmark) at a density of 6000 cells/well (for Celigo Imaging Cytometry) or into a Nunc 6-well plate at
a density of 150,000 cells/well (for fluorescence microscopy). After 24 h incubation for cell attachment,
the cells were incubated with either drug, DMSO or medium for 1 h, then stained with 5 µg/mL
Hoechst 33,342 and incubated for 1 h at 37 ◦C. Then, the cells were washed with ice-cold PBS to
remove excess Hoechst dye. Drugs were added again and the cells were incubated for 1h at 37 ◦C.
The plates were analyzed with either fluorescence microscopy (6-well plates) or imaging cytometry
(96-well plates). For the Celigo Imaging Cytometry (Lawrence, MA, USA), the application “Target 1
+ 2 (merge)” was used, and the mean fluorescence intensities were measured and data presented as
percentage of parental control.
2.6.2. MDCK-II-BCRP Cells
The inhibitory effect of SCO-201 on BCRP was determined in the Hoechst 33,342 accumulation
assay as described earlier [37]. Briefly, cells were pre-incubated with SCO-201 for 30 min and then
Hoechst 33,342 was added to a final concentration of 1 mM. Fluorescence was measured immediately
in constant intervals (60 s) for a period of 120 min with an excitation of 355 nm and an emission
wavelength of 460 nm at 37 ◦C using microplate readers (POLARstar and FLUOstar optima by BMG
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Labtech, Offenburg, Germany). Background fluorescence was subtracted and the average fluorescence
between 100 and 109 min obtained in the steady state was calculated and plotted against the logarithm
of the compound concentration. Dose–response curves were fitted by nonlinear regression using the
four-parameter or three-parameter logistic equation, whichever was statistically preferred (GraphPad
Prism, version 6.0, San Diego, CA, USA).
2.7. ATPase Assay
The effect of SCO-201 on the ATPase activity of human BCRP was measured using the PREDEASY
ATPase assay system (Solvo Biotechnology, (Sigma-Aldrich/Merck, Schnelldorf, Germany). The assay
is a modification of the method of Müller and Sarkardi et al. [38], and the procedure was carried out
according to the instructions provided by the manufacturer. Briefly, recombinant BCRP membranes
(provided by Solvo Biotechnology) were incubated in the presence or absence of vanadate and different
concentrations of either SCO-201 or SN-38, and incubated at 37 ◦C for 10 min. To test the effect of
SCO-201 on the sulfasalazine-stimulated ATPase activity of BCRP, the membranes were prepared
with sulfasalazine, prior to the incubation with SCO-201. To test the ability of SCO-201 to hinder
the stimulation of BCRP by SN-38, the membranes were prepared with either 0.5 or 1.5 µM SCO-201
and then incubated with different concentrations of SN-38. After incubation with test compounds,
MgATP was added to each well and incubated at 37 ◦C for 10 min. The ATPase reaction was
stopped by the addition of 1x Developer solution at room temperature (RT). Two minutes after, 100 µL
Blocker solution was added and the plate was incubated for 30 min at 37 ◦C for 30 min. The optical
densities were measured at 620 nm using a PowerWave X Microplate spectrophotometer (BioTek, Bad
Friedrichshall, Germany).
2.8. Molecular Interaction Modelling
Docking of SCO-201 and SN-38 in human BCRP transporter were performed using Glide,
Schrödinger Release, 2019-3, limited liability company (LLC) [39–41]. The 3D structure of BCRP was
obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB
ID: 6ETI) [16] and prepared using Protein Preparation Wizard, Schrödinger 2019-3, LLC [42]. SCO-201
and SN-38 were prepared using Ligprep, Schrödinger 2019-3, LLC, and docked using flexible XP
docking with sampling of both nitrogen inversions and ring conformations. Further characterization of
the binding between BCRP and the ligands were performed using the Desmond Molecular Dynamics
System, D.E. Shaw Research, Schrödinger, 2019-2, LLC [43]. A standard membrane was fitted to
the transmembrane domain of the transporter, and the system was saturated with ions and water
molecules. Simulation was run for 10ns and analyzed visually and using the Simulations Interactions
Diagram, Desmond, Schrödinger, 2019-2, LLC [43]. 2D docking graphics were produced from Desmond,
Schrödinger, 2019-2, LLC, and 3D molecular graphic images of docking were established using the
PyMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC.
2.9. In Vitro DMPK Analysis: Transporter Inhibition Analysis
Cells were seeded in a 96-well plate (20,000 cells/well) and used on days 2 or 3 post-seeding.
SCO-201 was prepared in assay buffer (HBSS-HEPES, pH 7.4), added to the cell plate and pre-incubated
at 37 ◦C for 15 min. SCO-201 was tested at either a single concentration (10 µM by default) or multiple
concentrations (0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 µM by default), with a final DMSO concentration of
1%. Subsequently, substrate was added to the plate followed by 20 min incubation at 37 ◦C. The plate
was then washed with cold assay buffer followed by fluorescence reading on a plate reader. The tested
transporters, cell lines, substrates, and reference inhibitors are shown in the Supplementary Materials
(Tables S1 and S2).
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2.10. In Vitro DMPK Analysis: CYP Inhibition
The following procedure was used to asses if SCO-201 inhibits the activity of common CYP
enzymes in pooled human liver microsomes in 96-well plate format. SCO-201 was pre-incubated with
substrate and human liver microsomes (mixed gender, pool of 50 donors, 0.1 mg/mL) in phosphate
buffer (pH 7.4) for 5 min in a 37 ◦C shaking waterbath. SCO-201 was tested at either a single
concentration (10 µM by default) with 0.1% DMSO or multiple concentrations (0.03, 0.1, 0.3, 1, 3, 10, 30,
and 100 µM by default) with up to 1% DMSO for IC50 determination. The reaction was initiated by
adding a Nicotinamide adenine dinucleotide phosphate (NADPH)-generating system. The reaction
was allowed for 10 min and stopped by transferring the reaction mixture to acetonitrile/methanol.
Samples were mixed and centrifuged. Supernatants were used for HPLC-MS/MS of the respective
metabolite. Tested CYP enzymes, substrates, metabolites, and reference inhibitors are shown in the
Supplementary Materials (Tables S2 and S3).
Data analysis: Peak areas corresponding to the metabolite were recorded. The percent of control
activity was calculated by comparing the peak area in the presence of the test compound to the control
samples containing the same solvent. Subsequently, the percent inhibition was calculated by subtracting
the percent control activity from 100. The IC50 value (concentration causing a half-maximal inhibition
of the control value) was determined by non-linear regression analysis of the concentration–response
curve using the Hill equation.
2.11. In Vitro DMPK Analysis: CYP Induction
The following procedure was carried out to test whether SCO-201 induces CYP1A, CYP2B6, and
CYP3A activities in human hepatocytes. The procedure was designed in accordance with the FDA
Guidance for Industry on Drug Interaction Studies (2006). Male and female human hepatocytes were
thawed and plated into collagen-coated 96-well plates in serum-containing medium (plating medium)
at a density of 0.7 × 106 viable cells/mL. The hepatocytes were cultured in a humidified incubator
at 37 ◦C and 5% CO2. At 4 h post plating, human hepatocytes were washed once with fresh plating
medium, followed by overnight incubation. At 24 h after plating, the plating medium was removed,
and the hepatocytes were overlaid with extracellular matrix (ECM) (Sigma) or Matrigel (BD) in the
serum-free medium (incubation medium), and then incubated for another 24 h. Incubation medium
with 0.1% DMSO was used as the negative control. After the 2-day recovery period, the hepatocytes
were treated with SCO-201 or a known inducer (Table S3) in the incubation medium on day 3 and day 4.
The known inducer was tested as the positive control. On day 5, the medium was removed, and the cells
were incubated with the respective CYP substrate in Krebs–Henseleit buffer (pH 7.4) containing 3 mM
salicylamide for 30 min. The reaction was terminated by transferring the incubation mixture to an equal
volume of acetonitrile/methanol mixture (1/1, v/v). Samples were mixed and centrifuged. Supernatants
are used for HPLC-MS/MS analysis of the corresponding metabolite. Peak areas corresponding to the
metabolite were recorded. The assay was rendered valid if enzyme activity with the positive control
was at least twofold greater than negative control.
2.12. Statistical Analyses
Statistical analyses were performed using Microsoft Excel. Means and standard deviations were
calculated for all quantitative data. For data represented in percentage (i.e., cell viability), the standard
deviations, determined from triplicate experiments, were calculated and displayed on the graphs





. Two-tailed, type 3 Student’s t-tests
were applied on datasets where relevant, in order to determine any significant statistical differences.
Statistical analysis of the data in the bidirectional transport assay was performed by comparing group
means with a Student’s t-test (two-tailed) or ANOVA, followed by Bonferroni’s multiple comparisons
test. The significance level was set to 5%, and thus p-values less than 0.05 were considered significant.
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3. Results
3.1. SCO-201 Reversed BCRP-mediated Drug Resistance in Chemotherapy Resistant Cells
To assess the potential BCRP-dependent re-sensitizing effects of SCO-201, we used the BCRP-
transduced canine kidney subline, MDCK-II-BCRP, which in several studies has been shown to express
high levels of BCRP [37,44]. The MDCK-II-BCRP cells are known to be less sensitive to chemotherapy
substrates of BCRP, such as SN-38, topotecan, and mitoxantrone, compared to their parental counterpart,
MDCK-II-WT [37,44]. We therefore tested the potential of SCO-201 to restore the drug sensitivity of the
MDCK-II-BCRP cells to SN-38 and mitoxantrone by treating the cells with either chemotherapy alone
or in combination with SCO-201, or the BCRP inhibitor Ko143 for comparison. As seen in Figure 2A-C,
SCO-201 was able to completely restore the response to SN-38 and mitoxantrone in the MDCK-II-BCRP
cells similar to the BCRP-inhibitor Ko143. The IC50 values are shown in Table 1. Treatment with
SCO-201 and SN-38 or mitoxantrone resulted in decreased IC50 values for the MDCK-II-BCRP cells
that were comparable to the IC50 values found for the MDCK-II-WT cells. Altogether, these results
show that SCO-201 significantly re-sensitized MDCK-II-BCRP cells to both SN-38 and mitoxantrone.
This is proof-of-concept that SCO-201 can affect BCRP-mediated resistance in a model system where
the resistance is engineered by ectopic overexpression of BCRP.
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Figure 2. SCO-201 reversed drug resistance in multidrug resistance (MDR) cells. Cell viability of
wild-type or breast cancer resistance protein (BCRP)-overexpressing MDCK-II cells and SN-38-sensitive
or -resistant HT29 cells. Cell viability is indicated as percentage of untreated control, and error bars
indicate percentage SD determined on the basis of n = 3–4. Note that some error bars might be invisible
due to the size of the data labels. Control conditions consisted of full growth medium. (A–C) Wild-type
and BCRP-overexpressing MDCK-II cells treated with either chemotherapy alone or in combination
with 10−5.5 µM SCO-201 or Ko143. (D–F) Parental and SN-38-resistant HT29 cells treated with either
chemotherapy alone or in combination with 1 µM SCO-201 or Ko143. Statistical difference (p < 0.05)
between mono-treatment and combination treatment of the resistant cell lines is marked by * (Student’s
t-test (two-tailed, type 3)).
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Table 1. IC50 values of anti-cancer drugs in the presence/absence of SCO-201 or Ko143.
IC50 Value (µM) for Each Cell Line
Drug/Drug Combination MDCK-II-WT MDCK-II-BCRP HT29PAR HT29SN-38-RES
SN-38 0.214 ± 0.023 1.956 ± 0.080 0.016 ± 0.010 0.463 ± 0.363
SN-38 + SCO-201 0.238 ± 0.029 0.007 ± 0.005
SN-38 + Ko143 0.437 ± 0.020 0.014 ± 0.021
Mitoxantrone 0.157 ± 0.023 1.060 ± 0.095
Mitoxantrone + SCO-201 0.214 ± 0.030
Topotecan 0.008 ± 0.003 0.121 ± 0.024
Topotecan + SCO-201 0.088 ± 0.030
Taken together, our results show that SCO-201 could successfully reverse resistance to the anti-cancer BCRP
substrates, SN-38, topotecan, and mitoxantrone, similarly to the BCRP inhibitor Ko143 in BCRP over-expressing
MDCK-II-BCRP and HT29SN-38-RES cells. This indicates that SCO-201 could be a modulator of BCRP activity.
Supplementary studies showed that SCO-201 has a dose-dependent effect with SN-38 in both MDCK-II-BCRP and
HT29SN-38-RES cells (Figures S3 and S4).
To further investigate the re-sensitizing effects of SCO-201 and to apply a more complex model
system of resistance, we tested the effects of SCO-201 in our DEN-50R in vitro model system of acquired
SN-38 resistance in colorectal cancer. To generate this system, the colorectal adenocarcinoma cell line,
HT29, was subjected to gradually increasing SN-38 concentrations for a period of ≈10 months, resulting
in an SN-38-resistant cell line (HT29SN-38-RES). Genome-wide expression mRNA profiling revealed
that BCRP was highly upregulated (25-fold) in the HT29SN-38-RES cells, compared to their parental
counterpart (HT29PAR) (GEO—Gene Expression Omnibus, NCBI, accession number GSE42387) [25].
We confirmed the BCRP overexpression with Western blot analysis (Figure S1). As seen in the blot,
two bands could be observed for BCRP in the HT29SN-38-RES cells, most likely due to the glycosylation
states of BCRP [45].
We tested the potential re-sensitizing effects of SCO-201 in the HT29SN-38-RES cells by treating the
cells with either chemotherapy alone or in combination with SCO-201 or Ko143. As seen in Figure 2D–F,
SCO-201 was able to significantly restore the response to both SN-38 and topotecan in the HT29SN-38-RES
cells, similar to the response observed for combinatorial treatment with Ko143. The IC50 values are
shown in Table 1. The IC50 values of SN-38 and topotecan decreased several folds for the HT29SN-38-RES
cells, following treatment with SCO-201, and they almost completely reached the IC50 values for the
HT29PAR cells (Table 1).
To investigate if these observations were due to general damaging effects on the cells that could
lead to general increase in sensitivity to chemotherapy, we applied oxaliplatin, which is not a substrate
for BCRP. When oxaliplatin was combined with either SCO-201 or Ko143 in the HT29SN-38-RES cells,
no added effects were observed (Figure S2). This suggests that the re-sensitizing effects were not due
to general cellular effects of either SCO-201 or Ko143.
3.2. SCO-201 Inhibited the BCRP-Mediated Flux Across Cell Membranes
To more directly investigate whether SCO-201 inhibits BCRP-mediated efflux transport, a series of
bidirectional transport experiments with the prototypical BCRP substrate [3H]-estrone-3-sulfate
were completed across monolayers of Caco-2 cells (Figure 3). In the absence of SCO-201,
the apparent permeability of [3H]-estrone-3-sulfate in the efflux direction (basolateral to apical)
was 2.7 ± 0.2 × 10−5 cm/second, whereas it was considerably lower in the opposite direction with an
apparent permeability of 2.2± 0.01× 10−6 cm/second. The resulting efflux ratio in the absence of SCO-201
was 12.2, which indicated a marked polarized transport in the efflux direction for [3H]-estrone-3-sulfate
across monolayers of Caco-2 cells. In the presence of 10 µM SCO-201, the apparent B-A (basolateral to
apical) permeability was significantly reduced to 9.6 ± 0.7 × 10−6 cm/second (p < 0.0001), whereas the
apparent permeability in the A-B (apical to basolateral) direction was significantly increased to
3.2 ± 0.3 × 10−6 cm/second (p = 0.0061). Correspondingly, the calculated efflux ratio was markedly
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reduced to 2.9, which together with the reduction in efflux transport of [3H]-estrone-3-sulfate
were clear indications that SCO-201 had an inhibitory effect on BCRP-mediated efflux transport
of [3H]-estrone-3-sulfate across Caco-2 cell monolayers (Figure 3).Cells 2020, 9, x FOR PEER REVIEW 10 of 22 
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Figure 3. Bidirectional transport of estrone-3-sulfate across Caco-2 cell monolayers in the presence
or absence of 10 µM SCO-201. Permeability (Papp) values were calculated from steady-state fluxes
as described the in the Methods section (Section 2.5). Filled bars show PA-B (apical to basolateral)
values, open bars show PB-A (basolateral to apical) values. Values are means ± SD of three individual
passages, with three individual permeable supports for each transport direction per passage (n = 3−5,
total N = 9). The p-values are indicated in the figure.
To further elucidate whether SCO-201 modulates BCRP and in this way triggers intracellular
accumulation of chemotherapy, we conducted dye efflux studies on wild-type and SN-38-resistant
HT29 cells, the latter of which overexpresses BCRP. The cells were stained with Hoechst in the presence
or absence of SCO-201, Ko143, or the MDR1/P-gp inhibitor PSC833 as a negative control. Figure 4
presents results from fluorescence microscopy and imaging cytometry analysis. Accumulation of
Hoechst could clearly be detected in the parental cells, whereas only low levels of Hoechst accumulation
could be detected in the BCRP-overexpressing chemotherapy-resistant cells (Figure 4A,B). When the
resistant cells were treated with either SCO-201 or Ko143, Hoechst accumulated to the level of the
parental control cells, whereas treatment with PSC833 did not have any effects (Figure 4A,B). In a
similar experiment, we quantified the dose-dependent effects of SCO-201 compared with Ko143 and
evaluated the outcome with imaging cytometry. Figure 4C shows the dose-dependent effect of SCO-201
on intracellular accumulation of dye in Hoechst-stained cells compared to Ko143. As seen from the
IC50 values, the potency of Ko143 (IC50 = 0.37 µM) and SCO-201 (IC50 = 0.45 µM) was almost identical.
Altogether, these results indicate that SCO-201, like Ko143, modulates the efflux of dye via BCRP,
resulting in an accumulation of Hoechst dye in the HT29SN-38-RES cells. The same tendency could be
observed when we quantified the effect of SCO-201 on the accumulation of Hoechst or Pheophorbic
A in the MDCK-II-BCRP cells (Figure S5 and S6). These Supplementary studies also indicated that
SCO-201 is likely not an inhibitor of MDR1/P-gp.
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3.3. The Drug-Stimulated ATPase Activity of BCRP Was Competitively Inhibited by SCO-201
Following our results from the flux studies (Figures 3 and 4), we further evaluated whether
SCO-201 indeed is a modulator of BCRP transport activity. To evaluate the modulatory effects of
SCO-201, we conducted ATPase studies to test the effect of SCO-201 on the ATPase activity of BCRP
in the presence or absence of another activating BCRP substrate. Figure 5A shows the relative
ATPase activities of BCRP incubated with either SCO-201 alone, or in the presence of the strong BCRP
activator, sulfasalazine. Sulfasalazine alone resulted in a maximal ATPase activity of 104.8 nmol Pi/mg
protein/min compared to the basal activity of 50.68 nmol Pi/mg protein/min (data not shown). As seen
on Figure 5A, SCO-201 was not in itself a stimulator of BCRP ATPase activity, and in the absence of
sulfasalazine, the ATPase activity of BCRP decreased dose-dependently upon incubation with SCO-201.
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When SCO-201 was added to sulfasalazine-stimulated BCRP, the ATPase activity of BCRP decreased
in a dose-dependent manner (Figure 5A). Then, we tested the effect of two different concentrations
of SCO-201 on SN-38-stimulated BCRP. Figure 5B,C shows the relative SN-38-stimulated ATPase
activity of BCRP in the presence or absence of either 0.5 µM or 1.5 µM SCO-201. In the presence of
SCO-201, the SN-38-stimulated ATPase activity of BCRP was shifted downwards, and the higher the
SCO-201 concentration, the higher the SN-38 concentration was needed to reach the maximal activity
of SN-38-stimulated BCRP. This revealed a typical competitive inhibition mechanism, showing that
SCO-201 competed for the drug binding to the active site of BCRP. Altogether our data indicate that
SCO-201 competitively inhibits the drug-stimulated ATPase activity of BCRP, suggesting that SCO-201
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activity of 104.8 nmol Pi/mg protein/min compared to the baseline activity of 50.68 nmol Pi/mg 
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Figure 5. SCO-201 inhibited drug-stimulated ATPase activity of BCRP. (A) The effect of increasing
concentrations of SCO-201 on basal and sulfasalazine-stimulated ATPase activity of BCRP. The data
are indicated as relative ATPase activity, normalized with respect to basal (untreated) and maximal
(sulfasalazine-stimulated) ATPase activity of BCRP. Sulfasalazine alone resulted in a maximal ATPase
activity of 104.8 nmol Pi/mg protein/min compared to the baseline activity of 50.68 nmol Pi/mg
protein/min. (B,C) The effect of 0.5 µM (B) and 1.5 µM (C) SCO-201 on SN-38-stimulated ATPase
activity of BCRP. Error bars on all graphs represent SD determined from duplicates.
3.4. Molecular Binding Model Further Supported a Competitive Action of SCO-201
Thus far, our results have indicated that SCO-201 competitively inhibits the transport of BCRP
substrates, such as SN-38, and that SCO-201 directly interacts with BCRP. To further support these
results, we performed in silico molecular docking simulations to identify the binding sites of SCO-201
or SN-38 in BCRP. SN-38 and SCO-201 were successfully docked into the 3D structure of the BCRP and
the resulting models showed that both SN-38 and SCO-201 were predicted to bind in the same binding
cavity (Figure 6). Docking scores were -12.24 for SN-38 and -8.66 for SCO-201, indicating that both
ligands could bind in the ligand binding site of the transporter.
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Figure 6. Docking of SN-38 and SCO-201 in the human BCRP transporter. The transporter is a
homomeric dimer with chain A (dark grey) and chain B (light grey). SN-38 (green) and SCO-201
(orange) bind in the same binding cavity when docked using Glide, Schrödinger, 2019-3, LLC [39–41].
Both the substrate SN-38 and the proposed inhibitor SCO-201 interacted with Phenylalanine (PHE)-439
in both chains of the protein through hydrophobic Pi-stacking interactions. SCO-201 formed a hydrogen
bond to Threonine (THR)-435, whereas SN-38 formed a hydrogen bond to Aspargine (ASN)-436.
Pi-stacking interactions are colored green and hydrogen bonds are colored violet.
The molecular dynamic simulations demonstrated that both ligands remained in the binding
sites throughout the sampled time period (Videos S1 and S2). The simulation interaction diagram
(Figure 7) showed that SN-38 interacted through pi-stacking interactions with Phenylalanine (PHE)-439
of both protein chains, whereas SCO-201 predominantly interacted with the PHE-439 residue of the B
chain and only to a lesser extent with the residue of the A protein chain (Figure 7; Figures S7 and S8).
SN-38 further formed a hydrogen bond to Aspargine (ASN)-436 residue of the B chain of the transporter,
whereas SCO-201 formed a hydrogen bond to both the Threonine (THR)-435 and ASN-436 residues of
the B chain (Figure 7). As SCO-201 binds in the same binding cavity and interacts with some of the
residues that the substrate SN-38 interacts with, it is likely that SCO-201 is a competitive inhibitor of
the BCRP transporter by blocking substrate access.
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3.5. In Vitro DMPKData Suggest That SCO-201 Is Not Likely to Increase The Risk of Pharmacokinetic Interactions
In clinical trials with ABC transporter inhibitors, pharmacokinetic interactions gave rise to
increased serum levels of chemotherapy, thus enhancing the toxic effects of the chemotherapy, and dose
reductions were therefore needed [34–38]. These dose reductions resulted in patients being under- or
even overdosed, as the pharmacokinetic profile of each individual patient was difficult to predict [46–50].
On the basis of this, we aimed to test the potential inhibitory effects of SCO-201 on common transporters,
playing a key role in pharmacokinetics, in order to predict the possibility that SCO-201 would negatively
influence the pharmacokinetic profile of co-administered drugs. Specifically, we tested the inhibitory
effects of SCO-201 on MDR1/P-gp as well as on several members of the solute carrier (SLC) family
involved in drug pharmacokinetics, in accordance with the European Medicines Agency (EMA)
Guidance of regulatory requirements for toxicological assessment of small molecules.
MDR1/P-gp and members of the SLC family including the organic anion transporting polypeptides
(OATP) OATP1B1, OATP1B3, organic anion transporter (OAT) OAT1 and organic cation transporters
(OCT) OCT2 act as major determinants of the absorption, distribution, excretion, and toxicity
(ADME-tox) properties of drugs [51,52]. To investigate if SCO-201 inhibits any of the aforementioned
transporters, we conducted a cell-based fluorometric drug transporter inhibition assay. We included
BCRP as a positive control. The results are presented in Table 2 and show that SCO-201 inhibited BCRP
as expected but is not likely an inhibitor of either MDR1/P-gp or any of the tested SLC family members
as none of the fluorometric substrates accumulated. In addition, it is seen that the IC50 value for BCRP
in CHO cells was 1.7 µM, showing that SCO-201 is a potent inhibitor of BCRP (Table 2 and Figure S7).
Table 2. Summary of drug transporter inhibition.
Transport Protein Cell Line Substrate IC50 (M)
OCT2 OCT2-CHO ASP+ NC
BCRP BCRP-CHO Hoechst 33342 1.7 × 10−6
OAT1 OAT-CHO CF NC
OAT3 OAT3-CHO CF NC
OATP1B1 OATP1B1-CHO FMTX NC
OATP1B3 OATP1B3-CHO FMTX NC
P-gp (MDR1) MDR1-MDCK-II Calcein-AM NC
NC: not calculable.
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To further predict any potential risk of drug–drug interactions, we tested the effect of SCO-201 on
key oxidative metabolic drug enzymes of the cytochrome P450 (CYP) family. Specifically, we tested
the potential inhibition or induction by SCO-201 on a range of common CYPs playing a key role in
determining the pharmacokinetic profile of drugs [53]. We used a standard CYP inhibition assay
based on human liver microsomes, and the IC50 values of SCO-201 towards CYP1A, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6, and CYP3A (with two substrates) were determined in a range of
concentrations (from 0.03 to 100 µM). The results are shown in Table 3 and found that no IC50 value
was less than 100 µM, suggesting that SCO-201 is not likely an inhibitor of these CYP isoforms and
may not cause CYP inhibition when its plasma concentration is below 100 µM.
Table 3. Cytochrome P450 (CYP) inhibition.
CYP Test Substrate IC50 (M)
CYP1A Human hepatocytes Phenacetin substrate >1 × 10−4
CYP2B6 Human hepatocytes Bupropion substrate NC
CYP2C8 Human liver microsomes Paclitaxel >1 × 10−4
CYP2C9 Human liver microsomes Diclofenac >1 × 10−4
CYP2C19 Human liver microsomes Omeprazole NC
CYP2D6 Human liver microsomes Dextromethorphan NC
CYP3A Human liver microsomes
Midazolam NC
Testosterone >1 × 10−4
NC: not calculable.
Inductions of CYP1A2, CYP2B6, and CYP3A4 by SCO-201 were tested at 1, 10, and 100 µM using
both enzyme activity and mRNA level changes as the end-points. The results are presented in Table 4.
Using enzyme activity as the end-point, the results were all below the cutoff value (40% of positive
control), suggesting that SCO-201 is not an inducer for these CYP isoforms. Using mRNA level as
the end-point, the results were also below the cutoff values, similarly suggesting that SCO-201 does
not induce the CYP isoforms. However, there was a trend in both enzyme and mRNA assays that
fold induction decreased with the increase in test concentrations. This trend may have resulted from
cytotoxicity toward the hepatocytes.
Table 4. CYP induction.
CYP Mean Fold Induction of mRNA at 1× 10−4 M Mean Fold Enzyme Activity Induction at 1 × 10−4 M
Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3
CYP1A 1 0.7 0.7
CYP1A2 0.24 0.39 0.26
CYP2B6 0.17 0.52 0.45 0.8 0.9 0.6
CYP3A 1.3 2.0 0.4
CYP3A 0.25 0.25 0.32
Fold induction = (activity of test compound treated cells)/(activity of negative control). mRNA fold induction =
(mRNA level in test compound treated cells)/(mRNA levels in vehicle treated controls).
In conclusion, our results from these in vitro analyses might imply that SCO-201 does not
significantly negatively influence the pharmacokinetic profile of co-administered drugs. This suggest
that SCO-201 may be of a new generation of ABC transporter modulators with low risk of increased
chemotherapy-mediated toxicity.
4. Discussion
ABC transporter-mediated resistance to multiple anti-cancer drugs is one of the major reasons for
cancer treatment failure [1–5]. Overexpression of the transporter BCRP prevents chemotherapeutic
agents such as SN-38, mitoxantrone, and fluoruracil from remaining inside cancer cells, and in this
way, protects the cancer cells from being killed by these drugs. BCRP expression in cancer cells
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confers drug resistance in leukemia, and higher levels are reported in solid tumors from the digestive
tract, endometrium, lung, and melanoma, although, contrarily, expression is generally low in breast
cancer tumours [54]. There is significant association between BCRP expression and tumor response to
chemotherapy and progression-free survival [1–4].
In this study, we showed that the pyrazolo-pyrimidine derivative SCO-201 can reverse MDR
in vitro by competitively inhibiting the transport function of BCRP. Firstly, we tested the ability
of SCO-201 to re-sensitize drug-resistant MDCK-II-BCRP and HT29SN-38-RES cells to chemotherapy,
and these data demonstrated that SCO-201 can successfully reverse resistance in these cells (Figure 2).
To investigate the potential mechanism of action of SCO-201, we conducted dye efflux assay and
examined the intracellular accumulation of Hoechst 33,342 in BCRP-overexpressing cells, when treated
with SCO-201, by fluorescence microscopy and imaging cytometry (Figure 4). Our results indicated
that SCO-201 triggers the accumulation of Hoechst 33,342 in the BCRP-expressing cells, similarly to
Ko143. We subsequently performed ATPase assay in order to examine if the effect of SCO-201 was
caused by a direct inhibition of the transport function of BCRP. These results showed that SCO-201
competitively inhibits the drug-stimulated activity of BCRP (Figure 5).
To further support these results, we performed molecular docking and molecular dynamics
simulations, and found that SCO-201 and SN-38 were predicted to bind in the same binding pocket of
BCRP. Both SN-38 and SCO-201 interacted with PHE-439 of the B protein chain through Pi-stacking
hydrophobic interactions, and ASN-436 through hydrogen bonds (Figures 6 and 7). From the cryo-EM
structure of BCRP (PDB ID: 6ETI), stacking interaction was also seen between the inhibitor and
PHE-439, which emphasized the importance of these residues both in transport and in inhibition of
BCRP. It further supports SCO-201 being a competitive inhibitor of the BCRP transporter [16].
There are challenges of bringing ABC transporter inhibitors to clinical use, reflected by the
fact that after 40 years of research there are still no approved ABC transporter inhibitors for use
in the clinical setting [1]. To date, three generations of different MDR1/P-gp inhibitors have been
tested and developed pre-clinically and clinically [1,7,9]. The first generation of inhibitors tested in
clinical trials were not specifically developed to modulate ABC transporters but were drugs already
in clinical use (e.g., verapamil and cyclosporine A). These were weak inhibitors and needed high
doses. Such high doses in combination with anti-cancer drugs (e.g., mitoxantrone, daunorubicin,
and etoposide) caused toxic side effects and had low therapeutic response [7–10]. Therefore, these were
quickly replaced by more potent and specific second-generation inhibitors (e.g., R-verapamil and
PSC-833 (Valspodar)) in order to reduce possible primary toxicities. In acute myeloid leukemia
(AML) patients, the combination of PSC-833 with anti-cancer drugs seemed to be beneficial for some
patients. However, the second-generation inhibitors were also shown to be inhibitors of CYPs and
displayed pharmacokinetic interactions leading to increased toxicity [7–10]. Several phase III clinical
studies with PSC-833 revealed that the combination with chemotherapeutic agents did not prolong
the survival of cancer patients [47,48,50,55]. Third-generation inhibitors (e.g., laniquidar (R101933),
ONT-093 (OC14–093), zosuqiodar (LY335979), elacridar (GF120918), and tariquidar (XR9576)) were up
to 200-fold more potent and had low pharmacokinetic interaction due to a limited CYP3A inhibition [56].
The third-generation inhibitors are well tolerated in humans, safe to combine with chemotherapy
due to less systemic pharmacokinetic interactions than previous MDR1 inhibitors, and were found to
cause potent MDR1/P-gp inhibition in humans [57–63]. Furthermore, scanning imaging of tumors for
contents of (99m)Tc-sestamibi before and after dosing of third generation inhibitors could possibly
be applied to identify subgroups of anti-cancer-resistant cancer patients who may benefit from a
combination of inhibitor and anti-cancer drug.
Thus, the development from first to third generation inhibitors has to a large degree abolished the
pharmacokinetic interactions and related toxicities with the tested inhibitors and anti-cancer drugs.
Even if toxicities should be observed with novel inhibitors and combinations with anti-cancer drugs,
this can be taken care of by starting a patient with an ABC transporter inhibitor and reduced dose of
chemotherapy. If no severe side effects are noted, the dose of chemotherapy can be increased at the
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next cycle. It is important to remember that, even with a need for lowering the dose of chemotherapy,
a significant anti-tumor effect might be obtained due to the simultaneous inhibition of drug efflux
pumps in the cancer cells. Another problem with the clinical studies, which tested the efficacy of
ABC transporter inhibitors in combination with chemotherapy, was the general lack of randomization,
and in most studies the ABC transporter inhibitor was not combined with the chemotherapy that
the patient had developed resistance against. Finally, the clinical studies also lacked the inclusion
of predictive biomarkers. In some of the studies, a few of the patients had ABC cassette proteins
measured in their tumor tissue, but in none of the studies was this performed on a fresh tumor biopsy,
and was instead performed on the primary biopsy obtained at the time of diagnosis and prior to any
chemotherapy, which does not necessarily reflect the expression of ABC transporter proteins in the
resistant tumor cells.
To our knowledge, no second or third generation BCRP inhibitors have been developed and tested
in clinical studies. The BCRP inhibitors tested so far are first generation inhibitors, which are developed
to inhibit other targets, and have pharmacokinetics interactions [64]. Some of the mechanisms by
which ABC transporter inhibitors could alter the pharmacokinetics of the anti-cancer agent include
competition for CYPs, intestinal or liver metabolism, inhibition of ABC transporter-mediated biliary
excretion or intestinal transport, or inhibition of renal excretion and elimination [65]. This means that
for an inhibitor to succeed, it needs to be non-toxic itself, and have no or low risk of interaction with
important pharmacokinetic proteins, such as CYPs.
In this study, in vitro DMPK analyses of SCO-201 demonstrated no inhibition or induction of CYPs
or SLCs whatsoever, suggesting a reduced risk of drug–drug interactions with other drugs, such as
chemotherapy (Tables 2–4). As mentioned, an obstacle for inhibitors to succeed in clinical development
is the fact that these also inhibit ABC transporters found in healthy tissues, which may lead to increased
toxic effects of chemotherapy. This is especially a problem with broad-spectrum inhibitors that interact
with many different efflux and uptake transporters, such as other ABC transporters or SLCs. However,
by applying a specific inhibitor, this will allow the other ABC transporters in healthy tissues to
compensate for the inhibition of the specific transporter, thereby protecting the healthy tissue from the
toxic effects of the chemotherapy. In contrast, the anti-cancer drug has induced an up-regulation of the
specific transporter in the resistant cancer cells, which will therefore be re-sensitized to the toxic effects
of the anti-cancer drug. Therefore, it is highly likely that the more specific the inhibitor, the lower is the
risk of increased toxicity. The specificity of SCO-201 to BCRP could provide benefits to the safety and
tolerability profile in co-medication in cancer treatment compared to application of broad-spectrum
inhibitors. Thereby, a BCRP-specific inhibition reduces the risk of potential drug–drug interactions in
co-medication, thus decreasing the risk for increased chemotherapy-mediated toxicity.
To our best knowledge, a specific BCRP inhibitor has never been in clinical testing. Future in vivo
studies of SCO-201 in combination with BCRP chemotherapy substrates should be conducted to
further examine the pharmacology and test for potential increased chemotherapy-mediated toxicity.
In such studies, we should utilize all the prior knowledge obtained with ABC transporter inhibitors.
This means that we should carefully select patients with acquired drug resistance (a prior benefit to the
chemotherapy in question), test for biomarkers such as cancer cell ABCG2 expression, start with a
reduced dose of chemotherapy (the chemotherapy that the patient had acquired resistance against,
and it should be an ABCG2 substrate drug) in combination with the inhibitor, perform randomization
of patients in order to include time-dependent end-points such as progression free survival and overall
survival, and perform a post-treatment association study between patient outcome and biomarkers.
In vivo pharmacokinetic studies of other pyrazolo-pyrimidine derivatives, such as Reversan [19,34],
have indicated that these do not cause increased toxicity of chemotherapy, and therefore it is possible
that SCO-201 also will not cause these unwanted toxic effects in vivo.
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5. Conclusions
Altogether, our data suggest that SCO-201 is a potential new drug candidate for the reversal
of BCRP-mediated resistance in cancer. SCO-201 appears to be a specific and potent inhibitor of
BCRP without affecting the CYP450 levels. Additionally, SCO-201 is stable in serum, has a favorable
pharmacokinetic, toxicological, and pharmacodynamic profile in mice, and is orally active [33].
We conclude that SCO-201 is a highly promising drug candidate for drug-resistant cancer where
overexpression of BCRP is the key mechanism of drug resistance.
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